

Journal of Visualized Experiments

Purification of platelets from mouse blood

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59803R2
Full Title:	Purification of platelets from mouse blood
Keywords:	Platelet Purification Mouse Platelet activation Iohexol Blood
Corresponding Author:	Md Nasimuzzaman, PhD Cincinnati Children's Hospital Cincinnati, OH UNITED STATES
Corresponding Author's Institution:	Cincinnati Children's Hospital
Corresponding Author E-Mail:	Md.Nasimuzzaman@cchmc.org;mdnasimuzzaman@yahoo.com
Order of Authors:	Md Nasimuzzaman, PhD Marilou G. Narciso
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Cincinnati, Ohio, USA

TITLE:**Purification of Platelets from Mouse Blood****AUTHORS AND AFFILIATIONS:**

Marilou G. Narciso¹, Md Nasimuzzaman^{1, 2}

¹Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

²University of Cincinnati College of Medicine, Cincinnati, OH

Email address:

Marilou G. Narciso (Marilou.Narciso@cchmc.org)

CORRESPONDING AUTHOR:

Md Nasimuzzaman

md.nasimuzzaman@cchmc.org

mdnasimuzzaman@yahoo.com

KEYWORDS:

Platelets, Purification, Mouse, Platelet Activation, Iohexol, Blood

SUMMARY:

Here, mouse blood was collected in the presence of an anti-coagulant. The platelets were purified by iohexol gradient medium using low speed centrifugation. The platelets were activated with thrombin to investigate if they were viable. The quality of the purified platelets was analyzed by flow cytometry and microscopy.

ABSTRACT:

Platelets are purified from whole blood to study their functional properties, which should be free from red blood cells (RBC), white blood cells (WBC), and plasma proteins. We describe here purification of platelets from mouse blood using three-fold more iohexol gradient medium relative to blood sample volume and centrifugation in a swinging bucket rotor at 400 x *g* for 20 min at 20 °C. The recovery/yield of the purified platelets were 18.2-38.5%, and the purified platelets were in a resting state, which did not contain any significant number of RBC and WBC. The purified platelets treated with thrombin showed up to 93% activation, indicating their viability. We confirmed that the purified platelets are sufficiently pure using flow cytometric and microscopic evaluation. These platelets can be used for gene expression, activation, granule release, aggregation, and adhesion assays. This method can be used for purification of platelets from the blood of other species as well.

INTRODUCTION:

Platelets are a component of blood that functions as an initiator of blood clotting in response to damage in the blood vessel. They gather at the site of injury to plug the vessel wall¹. Platelets are anucleate fragments of cytoplasm derived from the megakaryocytes of the bone marrow under

the influence of thrombopoietin and enter the circulation². They are considered as metabolically active and capable of sensing extracellular environment by activating intracellular signaling cascades that result in platelet spreading, aggregation, and hemostatic plug formation^{1,3}. Besides hemostasis/thrombosis and wound healing⁴, platelets play an important role in host inflammatory responses, angiogenesis, and metastasis^{3,5-8}.

Platelets are purified from blood to study their biochemical and physiological properties, which should be free from other blood components. Since red blood cells (RBC) and white blood cells (WBC) contain significantly more RNA and proteins than platelets^{9,10}, the presence of even a small number of these cells can interfere with transcriptomic and proteomic analyses of RNA and proteins derived from platelets. We found that purified platelets activated with thrombin bind antibody such as anti-GPIIb/IIIa (JON/A) and anti-P-selectin more efficiently than whole blood platelets.

Since platelets are fragile, it is important to treat the samples as mildly as possible. If the platelets are activated, they release their granule contents and ultimately degrade. Therefore, to keep the platelets' functional properties intact, it is important to maintain platelet quiescence during isolation. Several protocols have described isolation of platelets from human, dog, rat, and non-human primate by various methods^{1,10-12}. Some of the methods require multiple steps such as collection of platelet-rich plasma by centrifugation, filtration by separation column, negative selection of platelets with RBC- and WBC-specific antibody conjugated to magnetic beads, and so on, which are time-consuming and may degrade platelets and their contents.

Ford and his colleagues described platelet purification from human blood using iohexol medium¹¹. This method uses a similar volume of blood sample and medium during purification. Since humans yield a higher volume of blood, it is relatively easy to purify the platelets.

Iohexol is a universal density gradient inert medium that is freely soluble in water and used in the fractionation of nucleic acids, proteins, polysaccharides, and nucleoproteins^{13,14}. It has low osmolality and is non-toxic, thus making it an ideal medium for purification of intact living cells¹¹. It is a non-particulate medium; therefore, the distribution of cells in a gradient can be determined using hemocytometer, flow cytometer, or spectrophotometer. It does not interfere with most of the enzymatic or chemical reaction of the cells or cellular fragments after dilution.

The mouse serves as an important animal model for many human diseases¹⁵⁻¹⁸. There are a few published articles that describe purification of mouse platelets^{19,20}. However, the mouse yields a relatively smaller volume of blood, which makes it difficult to purify platelets. If the same small volume of gradient medium and blood samples is used, the platelet layer cannot be clearly separated from RBC-WBC layer after centrifugation. In this article, we have described a quick and simple method of mouse platelet purification with three-fold more iohexol gradient medium relative to the blood sample volume and low speed centrifugation. We have also activated the purified platelets with thrombin and investigated their quality with flow cytometry and microscopy.

PROTOCOL:

Mouse blood collection should be conducted with appropriate institutional animal care and use committee approval.

NOTE: The platelet purification protocol is described in a flow diagram in **Figure 1**.

1. Collection of blood

1.1. Add 25 μ L of 3.2% sodium citrate (pH 7.2) as an anti-coagulant and 0.4 mM of Gly-Pro-Arg-Pro (GPRP) in a polypropylene tube.

1.2. Collect approximately 200 μ L of blood from the C57BL/6 mouse using retro-orbital bleeding.

NOTE: Blood can be collected from any type of mouse strain regardless of age or gender.

1.2.1. Use 2 mL of isoflurane in any type of chamber to anesthetize the mouse.

Note: Depth of anesthesia is checked by signs of increased respiration and decreased movement. The mouse should not respond to movement of the anesthesia chamber, or to being handled. If the mouse is responsive to movement and handling, it requires more time to keep in the anesthesia chamber.

1.2.2 Open either right or left eyelid of the mouse and insert a 7.5 cm (0.12 cm diameter) capillary tube into the vascular plexus of the eye.

1.2.3. Twist the capillary tube one half turn while applying pressure to the capillary tube to break the vessels and initiate blood flow. Hold the animal upside down over the collection vial to be filled by capillary action.

1.2.4. Once the appropriate volume of blood is collected, remove the capillary tube and close the eye by applying mild pressure for 30 s on the eyelid with gauze. Once bleeding is stopped, return the mouse to its cage and monitor for bleeding.

1.2.5. Check eyes for trauma 1-2 days after retro-orbital bleeding. Remove any mouse from the study showing signs of significant trauma to the eye as a result of the procedure and euthanize.

NOTE: The mouse should not undergo any kind of treatment which can inhibit platelets for at least two weeks before blood collection. The blood sample must be used for platelet purification within one hour of bleeding the mouse.

2. Platelet purification

NOTE: Platelet purification should be carried out at room temperature to prevent their degradation. Make sure that temperature of the reagents and instruments are between 18 to 22 °C. To prevent platelet degradation, fast pipetting and vigorous shaking should be avoided during the procedure.

2.1. Add 600 µL of iohexol gradient medium (12% iohexol powder in 0.85% sodium chloride, 5 mM Tricine, pH 7.2)¹¹ into an 1.5 mL tube.

2.2. Add 200 µL of blood sample slowly down the side of the tube on top of the gradient medium with a wide bore pipette tip so that blood and iohexol medium do not mix (Figure 2A).

2.3. Centrifuge the sample containing tube at 400 x g for 20 min at 20 °C in a swinging bucket rotor with slow acceleration and deceleration.

2.4. Collect most of the platelet-rich layer and a small fraction of platelet-poor layer (total 300 to 400 µL) using a wide bore pipette tip without disturbing the RBC and WBC layers (Figure 2B). Transfer the platelet sample to a new tube.

NOTE: If the platelet count is less in the blood or a smaller volume of blood is used, the platelet-rich layer and platelet-poor layer can be seen as a single layer.

2.5. Add 1 mL of PBS to the platelet sample, mix by inverting, and centrifuge at 800 x g for 10 min at 20 °C in a swinging bucket rotor. Discard the solution completely and add 200 µL of PBS to resuspend the platelets with mild pipetting.

NOTE: This step is optional, as it removes the gradient medium and plasma proteins and increases the sensitivity of platelets to agonists such as thrombin. Since different centrifuges have different programs, the slow acceleration/deceleration can be determined by reading the user manual of the centrifuge.

2.6. Transfer 30 µL of this sample into a new tube to count platelets. The remaining platelets can be used for biochemical and physiological assays such as platelet activation, aggregation, granule release, etc.

2.7. For RNA or protein extraction, centrifuge the platelet sample at 800 x g for 10 min to pellet the platelets. Discard supernatant completely without disturbing the pellet. Add the desired volume of RNA or protein lysis buffer to lyse the platelets.

3. Counting the platelets

3.1 Count the whole blood cells without dilution and purified platelets (diluted 2 to 5-fold with PBS) using an automated cell analyzer. Use 30 to 50 µL samples for counting.

3.2. Calculate the total number of platelets by multiplying by the volume of the sample.

3.3. Calculate the percentage of yield/recovery of purified platelets.

3.4. Count the RBC and WBC in the purified platelet sample (diluted 50 to 100-fold with PBS) with a hemocytometer and microscope.

4. Platelet activation

4.1. In a tube, add 1 to 2 million purified platelets in up to 100 μ L of staining buffer (PBS with 2% fetal bovine serum, FBS).

4.2. For multiple number of samples, make a master mix of antibodies with 1 μ L (0.5 mg/mL) of the following: PE-Cy7 rat anti-mouse TER 119, PE rat anti-mouse CD45, FITC rat anti-mouse CD41, and APC rat anti-mouse/human CD62P (P-selectin) to detect RBC, WBC, platelets, and activated platelets, respectively. Add the master mix to the tubes for staining the cells. Do not add thrombin.

4.3. In another tube, add 1 to 2 million of purified platelets in up to 100 μ L of staining buffer, and 0.4 mM GPRP peptide. Add thrombin to activate the platelets and stain the cells following step 4.2.

NOTE: GPRP should be added to the sample before adding thrombin to prevent aggregate or clot formation through platelet activation. Thrombin concentration should be optimized to obtain good activation of platelets. After platelet activation, event counts are decreased during acquisition of samples by flow cytometry.

4.3. As a positive control, add 1 μ L of whole blood in up to 100 μ L staining buffer in a tube and 0.4 mM GPRP peptide. Add thrombin to activate platelets. As a negative control, add 1 μ L of whole blood in up to 100 μ L of staining buffer. Do not add thrombin in negative control sample. Stain the cells following step 4.2.

4.4. For flow cytometry isotype control, label 5 tubes with unstained, PE-Cy7, PE, FITC, and APC. Add 100 μ L of staining buffer, 1 μ L of blood, and 1 μ L of the respective antibody to the labeled tubes to stain the cells.

4.5. Incubate samples to stain for 30 min at room temperature in the dark.

4.6 Wash the samples by adding 1 mL of staining buffer to each tube. Centrifuge at 800 $\times g$ for 5 min at room temperature. Discard the staining buffer carefully without dislodging the pellet.

4.7 Add 300 μ L of staining buffer to each tube, mix mildly, and transfer to a FACS tube. Store the stained samples in the dark until analyzed with a flow cytometer.

5. Flow cytometry analyses of platelets

5.1. Create a new experiment and generate log forward scatter vs log side scatter dot plots and assign gates for Ter119 PE-Cy7 (RBC), CD45 PE (WBC), CD41 FITC (platelets), and CD62P APC (activated platelets) populations according to the gating strategy chosen for the experiment in the FACS DIVA software.

5.1.1. Open the population hierarchy by choosing **Show Population Hierarchy** under the **Populations** tab. Edit the population hierarchy by checking the gating strategy and properly renaming the gates.

5.1.1. Open statistics view by choosing **Create Statistics View**. Edit statistics view according to user preferences by right clicking the statistics view and selecting **Edit Statistics View**.

5.1.3. Choose a color for each gate that enhances the visual aspect of the layout by double clicking on the box corresponding to the population.

5.2. In the **Cytometer** window, click on the **Parameters** tab and adjust the voltages for parameters to visualize the population of interest on the plots.

5.3. Adjust voltages for each of the parameters so that the negative population can be distinguished from the positive population. Before recording the samples for the compensation control, check that the single-stained positive controls are on scale (ensure that the positive peaks are visible and not too far to the right).

NOTE: If the positive peaks are off scale, the voltages should be adjusted to see the positive populations.

5.4. Record the single-color stained cells for compensation controls (unstained, PE-Cy7, PE, FITC, and APC).

5.5. If the positive control gates are not set up properly, adjust them by changing voltages.

5.6. Go to **Experiment > Compensation Setup > Calculate Compensation**. Choose **Apply Only** in the resulting window.

5.7. Switch to the global worksheet by clicking on the toggle button in the top, left of the worksheet window.

5.8. Load the positive control sample and acquire enough cells to adjust the compensation and the gates.

5.9. Load the sample again and check that each plot shows the expected cell population based on the fluorochrome stained antibody. Acquire and record 100,000 events for whole blood

samples and 10,000 events for purified platelets. Load the samples one by one until acquisition is completed.

5.10. Analyze the flow cytometry data with the software with appropriate plots and gates (**Figure 3**)

REPRESENTATIVE RESULTS:

The summary of platelet purification is described in a flow diagram (**Figure 1**). Steps include collection of blood from mouse using retro-orbital bleeding in the presence of an anticoagulant, addition of blood sample onto the iohexol gradient medium, centrifugation in a swinging bucket rotor at 400 x *g* for 20 min at 20 °C. The quality of the purified platelets was evaluated with microscopy and flow cytometry after staining with antibody to detect any contaminating cells and activated platelets.

The iohexol gradient medium and the blood sample formed two separate layers in the tube if the blood was slowly added onto the medium (**Figure 2A**). However, if there is delay in this step, most of the blood sample could diffuse into the medium and it might be difficult to purify the platelets. The wide-bore pipette tips ensured no physical stress to the platelets which is important for maintaining integrity of the platelets and preventing their degradation. During centrifugation, slow acceleration helped prevent inadvertent mixing of the blood sample with iohexol medium and slow deceleration helped maintain the gradient after centrifugation. The top (straw color) layer contained the plasma and did not contain any types of intact blood cells, the second layer (whitish) from the top contained majority of the platelets which was collected using a wide-bore pipette tip, the third layer (transparent) was platelet poor which was partly collected carefully to avoid aspiration of bottom layer (red) RBC and WBC (**Figure 2B**). The platelet-rich layer and platelet poor layer could not be seen separated if the platelet counts were low in the blood sample. The RBC and WBC layer could not be seen as separate layers since blood volume was small. However, WBC forms a white layer, called buffy coat between platelet poor layer and RBC layer if a larger volume of blood is used for purification^{10,11}. It is important to carry out the whole procedure at 18 to 22 °C. Both the higher temperature and refrigeration of the samples yielded lower platelet counts due to degradation.

We found 18.2 to 38.5% ($27.1 \pm 6.5\%$, *n*=12) recovery/yield of the purified platelets. To investigate their viability, purified platelet samples were activated with thrombin. Flow cytometric analysis of platelets samples were done after staining with the markers for platelets, activated platelets, RBC, and WBC. The whole blood showed distinct populations of RBC, WBC, and platelets on a logarithmic forward scatter vs side scatter dot plot (**Figure 3A**), whereas the purified platelets showed a distinct population with negligible numbers of RBC and WBC (**Figure 3B**). The whole blood showed RBC and WBC after staining them with anti-mouse Ter119 and anti-mouse CD45 antibody (**Figure 3C**) whereas the purified platelets showed negligible number of RBC and WBC (**Figure 3D**). We evaluated the purified platelet sample with a microscope and did not see any significant number of intact RBC and WBC. Therefore, the RBC and WBC events which were shown in **Figure 3D** might be the fragments of RBC and WBC containing Ter119 and CD45, respectively. Purified platelets which were not treated with thrombin showed almost no

activation indicating their resting state (**Figure 3E**), whereas purified platelets treated with thrombin showed 71% activation (up to 93% activation was observed in some samples) (**Figure 3F**) indicating their viability. We also performed microscopic evaluation of purified platelet samples not treated with thrombin which showed no platelet aggregation (**Figure 4A**), however, purified platelets formed aggregates after being treated with thrombin (**Figure 4B**), which further indicate their viability. Based on flow cytometric and microscopic studies, we confirmed that our purified platelets were good quality.

Figure Legend

Figure 1. Schematic diagram for mouse platelet purification. Blood sample from mouse is collected in the presence of an anticoagulant. The blood sample is slowly added onto the Iohexol gradient medium and centrifuged at $400 \times g$ for 20 min at 20°C . The platelet layer is transferred to a new tube. The quality of purified platelets is checked with microscopy and flow cytometry. The platelets can be used immediately or stored at -80°C .

Figure 2. Mouse blood before and after centrifugation with Iohexol gradient medium. (A) Iohexol and blood form two separate layers before centrifugation if the blood sample is added carefully. Left panel shows schematic diagram and right panel shows the actual image. **(B)** Four separate layers are seen after centrifugation of whole blood with gradient medium. Left panel shows schematic diagram of the layers and right panel shows the actual image.

Figure 3. Flow cytometric analysis of purified platelets. (A) Whole blood shows RBC, WBC, and platelet populations. **(B)** Purified platelets show minor numbers of RBC and WBC events. **(C)** Whole blood shows RBC and WBC after staining with anti-mouse Ter119 and anti-mouse CD45. **(D)** Purified platelets show negligible number of RBC and WBC events after staining with anti-mouse Ter119 and anti-mouse CD45. **(E)** Purified platelets stained with anti-mouse CD41 and anti-mouse/human P-selectin show almost no platelet activation. **(F)** Purified platelets treated with thrombin and stained with anti-mouse CD41 and anti-mouse/human P-selectin show activation of platelets.

Figure 4. Microscopic evaluation of purified platelets. (A) Purified platelets do not show any aggregation. **(B)** Purified platelets treated with thrombin show aggregation. Both figures are $200\times$ magnification, ocular lens $10\times$ and objective lens $20\times$.

DISCUSSION:

Commonly, platelets are isolated by low-speed centrifugation which yields platelet-rich plasma that contains a significant number of blood cells, cellular debris, and plasma proteins which can interfere with the biochemical and physiological assays and needs further purification²¹. Therefore, it is important to use a rapid and simple method which can yield pure platelets without major contaminants. The protocol presented here describes the purification of platelets from mouse blood using a gradient medium with low speed centrifugation. The parameters used in this protocol maximize the yield and minimize the degradation of platelets. The gradient medium and plasma proteins can be removed by including a washing step after

platelet collection which can increase the sensitivity of platelets to agonist or antibody. Most importantly, the purified platelets are in resting state, but they can be activated in the presence of an agonist, such as thrombin. We have found that thrombin activity varies from one source to another. Therefore, thrombin concentration should be optimized empirically to obtain good activation of platelets.

Due to a small volume of mouse blood, it is inconvenient to purify platelets because platelets can be mixed with RBC and WBC during aspiration. We have resolved this issue by optimizing the ratio of blood sample and gradient medium. We have found that three-fold more gradient medium relative to the blood volume can clearly separate the platelet layer from the serum and RBC-WBC layers which facilitates easy collection of pure platelets.

Platelet purification should be carried out at room temperature between 18 to 22 °C to prevent their degradation. It has been reported that platelets degrade if stored in the refrigerator or temperatures above 27 °C¹¹. Fast pipetting and vigorous shaking should be avoided to prevent platelet degradation during purification. Since different centrifuges have different programs, the acceleration/deceleration should be determined empirically to maintain the gradient.

If several mouse blood samples are used in the purification, the bleeding should be done in less than one hour and purification should be completed within next one hour. If blood samples are left for more than 2 hours, platelets cannot be purified due to their degradation. If more platelets are needed for any study, the mouse blood can be collected by terminal procedures such as cardiac puncture or inferior vena cava bleeding, which yield 800 to 1000 µL blood, and platelet purification should be carried out in multiple tubes and combined after purification.

In conclusion, we have described a simple and rapid protocol for platelet purification from a small volume of mouse blood. This method can also be used for platelet purification from other species as well. The purified platelets can be used for gene expression, activation and granule release, aggregation, and adhesion assays upon stimulation with various agonists.

ACKNOWLEDGEMENTS

This work was supported by a start-up funding of Cincinnati Children's Research Foundation and a University of Cincinnati Pilot Translational grant to M.N.

DISCLOSURES

The authors declare no conflict of interest.

REFERENCES

- 1 de Witt, S. M., Verdoodt, R., Cosemans, J. M., Heemskerk, J. W. Insights into platelet-based control of coagulation. *Thrombosis Research*. **133 Suppl 2** S139-148, doi:10.1016/S0049-3848(14)50024-2 (2014).
- 2 Machlus, K. R., Thon, J. N., Italiano, J. E., Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet

formation. *British Journal of Haematology*. **165** (2), 227-236, doi:10.1111/bjh.12758 (2014).

3 Weyrich, A. S., Zimmerman, G. A. Platelets: signaling cells in the immune continuum. *Trends in Immunology*. **25** (9), 489-495, doi:10.1016/j.it.2004.07.003 (2004).

4 Nami, N. et al. Crosstalk between platelets and PBMC: New evidence in wound healing. *Platelets*. **27** (2), 143-148, doi:10.3109/09537104.2015.1048216 (2016).

5 Mancuso, M. E., Santagostino, E. Platelets: much more than bricks in a breached wall. *British Journal of Haematology*. **178** (2), 209-219, doi:10.1111/bjh.14653 (2017).

6 Hampton, T. Platelets' Role in Adaptive Immunity May Contribute to Sepsis and Shock. *Journals of the American Medical Association*. **319** (13), 1311-1312, doi:10.1001/jama.2017.12859 (2018).

7 Sabrkhany, S., Griffioen, A. W., Oude Egbrink, M. G. The role of blood platelets in tumor angiogenesis. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*. **1815** (2), 189-196, doi:10.1016/j.bbcan.2010.12.001 (2011).

8 Menter, D. G. et al. Platelet "first responders" in wound response, cancer, and metastasis. *Cancer and Metastasis Reviews*. **36** (2), 199-213, doi:10.1007/s10555-017-9682-0 (2017).

9 Fink, L. et al. Characterization of platelet-specific mRNA by real-time PCR after laser-assisted microdissection. *Thrombosis and Haemostasis*. **90** (4), 749-756, doi:10.1160/TH03-02-0095 (2003).

10 Trichler, S. A., Bulla, S. C., Thomason, J., Lunsford, K. V., Bulla, C. Ultra-pure platelet isolation from canine whole blood. *BioMed Central Veterinary Research*. **9** 144, doi:10.1186/1746-6148-9-144 (2013).

11 Ford, T. C., Graham, J., Rickwood, D. A new, rapid, one-step method for the isolation of platelets from human blood. *Clinica Chimica Acta*. **192** (2), 115-119, doi:10.1016/0009-8981(90)90075-4 (1990).

12 Noisakran, S. et al. Infection of bone marrow cells by dengue virus in vivo. *Experimental Hematology*. **40** (3), 250-259 e254, doi:10.1016/j.exphem.2011.11.011 (2012).

13 Rickwood, D., Ford, T., Graham, J. Nycodenz: a new nonionic iodinated gradient medium. *Analytical Biochemistry*. **123** (1), 23-31, doi:10.1016/0003-2697(82)90618-2 (1982).

14 Graham, J. M., Ford, T., Rickwood, D. Isolation of the major subcellular organelles from mouse liver using Nycodenz gradients without the use of an ultracentrifuge. *Analytical Biochemistry*. **187** (2), 318-323, doi:10.1016/0003-2697(90)90463-J (1990).

15 Milligan, G. N. et al. A lethal model of disseminated dengue virus type 1 infection in AG129 mice. *Journal of General Virology*. **98** (10), 2507-2519, doi:10.1099/jgv.0.000923 (2017).

16 Strassel, C. et al. Lentiviral gene rescue of a Bernard-Soulier mouse model to study platelet glycoprotein Ibbeta function. *Journal of Thrombosis and Haemostasis*. **14** (7), 1470-1479, doi:10.1111/jth.13355 (2016).

17 Bergmeier, W., Boulaftali, Y. Adoptive transfer method to study platelet function in mouse models of disease. *Thrombosis Research*. **133 Suppl 1** S3-5, doi:10.1016/j.thromres.2014.03.002 (2014).

439 18 Bakchoul, T. et al. Recommendations for the use of the non-obese diabetic/severe
440 combined immunodeficiency mouse model in autoimmune and drug-induced
441 thrombocytopenia: communication from the SSC of the ISTH. *Journal of Thrombosis and*
442 *Haemostasis*. **13** (5), 872-875, doi:10.1111/jth.12879 (2015).

443 19 Aurbach, K., Spindler, M., Haining, E. J., Bender, M., Pleines, I. Blood collection, platelet
444 isolation and measurement of platelet count and size in mice-a practical guide. *Platelets*.
445 1-10, doi:10.1080/09537104.2018.1528345 (2018).

446 20 Jirouskova, M., Shet, A. S., Johnson, G. J. A guide to murine platelet structure, function,
447 assays, and genetic alterations. *Journal of Thrombosis and Haemostasis*. **5** (4), 661-669,
448 doi:10.1111/j.1538-7836.2007.02407.x (2007).

449 21 Birschmann, I. et al. Use of functional highly purified human platelets for the
450 identification of new proteins of the IPP signaling pathway. *Thrombosis Research*. **122**
451 (1), 59-68, doi:10.1016/j.thromres.2007.08.022 (2008).








Figure 2

A

← Blood sample

← Iohexol medium

B

← Plasma layer

← Platelet-rich layer

← Platelet-poor layer

← RBC and WBC layer

Figure 3

[Click here to access/download;Figure;Figure 3.pdf](#)






Figure 4**A****B**

Name of Material/ Equipment	Company	Catalog Number
APC rat anti-mouse/human CD62P (P-selectin)	Thermoscientific	17-0626-82
Eppendorf tube	Fisher Scientific	14-222-166
FACS DIVA software	BD Biosciences	Non-catalog item
FACS tube	Fisher Scientific	352008
Fetal bovine serum (FBS)	Invitrogen	26140079
FITC rat anti-mouse CD41	BD Biosciences	553848
Flow cytometer	BD Biosciences	Non-catalog item
FlowJo software	FlowJo, Inc.	Non-catalog item
Gly-Pro-Arg-Pro (GPRP)	EMD Millipore	03-34-0001
Hematocrit Capillary tube	Fisher Scientific	22-362566
Hemavet	Drew Scientific	Non-catalog item
Hemocytometer	Hausser Scientific	3100
Isoflurane	Baxter	1001936040
Microscope (Olympus CKX41)	Olympus	Non-catalog item
Nycodenz (Histodenz)	Sigma-Aldrich	D2158
PE rat anti-mouse CD45	BD Biosciences	561087
PE-Cy7 rat anti-mouse TER 119	BD Biosciences	557853
Pipet tips 200 µL, wide-bore	ThermoFisher Scientific	21-236-1A
Pipet tips 1000 µL, wide-bore	ThermoFisher Scientific	21-236-2C
Phosphate buffured saline (PBS)	ThermoFisher Scientific	14040-117
Sodium chloride	Sigma-Aldrich	S7653
Sodium citrate	Fisher Scientific	02-688-26
Staining buffer	In-house	Non-catalog item
Steile water	In-house	Non-catalog item
Table top centrifuge	ThermoFisher Scientific	75253839/433607
Thrombin	Enzyme Research Laboratoty	HT 1002a
Tricine	Sigma-Aldrich	T0377

Comments/Description
Platelets activation marker
Tube for centrifuge
Analysis of platelets and whole blood
Tubes for flow cytometry
Ingredient for staining buffer
Platelets marker
Analysis of platelets and whole blood
Analysis of platelets and whole blood
Prevent platelet clot formation
Blood collection capillary tube
Blood cell analyzer
Cell counting chamber
Use to Anesthetize mouse
Cell monitoring and counting
Gradient medium
WBC marker
RBC marker
Transferring blood and platelet samples
Transferring blood and platelet samples
Buffer for washing and dilution
Physiological saline
Anti-coagulant
Wash and dilution buffer
Solvent
Swinging bucket rotor centrifuge
Platelet activation agonist
Buffer for Nycodenz medium



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

purification and activation of platelets from mouse blood

Author(s):

marilou G. Narciso and Md Nasimuzzaman

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JOVE"** means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JOVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JOVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JOVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JOVE agreeing to publish the Article, the Author hereby grants to JOVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JOVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Md Nasimuzzaman

Department:

Pediatrics, Division of Experimental Hematology

Institution:

Cincinnati Children's Hospital and Cancer Biotech

Title:

Instructor (Faculty Member)

Signature:

MdNasimuzzaman

Date:

4/04/2013

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

To
Editor
The Journal of Visualized Experiments

Dear Editor,

We would like to thank you for inviting us to revise our manuscript, JoVE59803 "Purification of platelets from mouse blood" for consideration of publication in *the Journal of Visualized Experiments*.

We are submitting the revised manuscript to address the comments of the editor. All changes are highlighted in the revised manuscript. Here are the responses to the editorial comments:

1. Please copy-edit the manuscript as there are scattered typos.

Response: We have edited the entire manuscript for typos.

2. Please address the comments in the attached manuscript.

Response: We have addressed the comments of the editor mentioned in the manuscript. Highlighted.

3. Please highlight 2.75 pages of protocol text for inclusion in the video. This is a hard production limit to ensure that videography can occur in a single day.

Response: We have highlighted 2.75 pages of protocol text for inclusion in video. Highlighted in yellow

4. Please do not abbreviate journal titles in the References.

Response: We have corrected journal titles in the References.

The data of this manuscript is original and is not under consideration elsewhere. Both authors have read and approved the contents of the manuscript and its submission to the JOVE.

Thank you for your consideration.

Sincerely,

Md Nasimuzzaman, Ph.D.
Corresponding author
Date: 3/22/2019

